<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362035</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-005</org_study_id>
    <nct_id>NCT02362035</nct_id>
  </id_info>
  <brief_title>ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies</brief_title>
  <acronym>KEYNOTE145</acronym>
  <official_title>A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and&#xD;
      pembrolizumab in hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, nonrandomized study that will be conducted in 2 stages. In&#xD;
      the first stage, Part 1 of the study will determine the safety and preliminary efficacy of&#xD;
      acalabrutinib and pembrolizumab in a limited group of B-cell malignancies. In the second&#xD;
      stage, Part 2 allows for possible expansion cohorts into a wider range of B-cell&#xD;
      malignancies, and Part 3 will evaluate the combination in subjects with myelofibrosis (MF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 20, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Actual">July 14, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Follicular Lymphoma (FL)</condition>
  <condition>CLL</condition>
  <condition>Small Lymphocytic Lymphoma (SLL)</condition>
  <condition>Richter's Syndrome</condition>
  <condition>Mantle Cell Lymphoma (MCL)</condition>
  <condition>Indolent Non Hodgkin Lymphoma</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Marginal Zone Lymphomas</condition>
  <condition>Mediastinal Large B Cell Lymphoma</condition>
  <condition>Hairy Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>ACP-196 (Acalabrutinib) +PEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PART 1 &amp; PART 2- Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) in combination with Pembrolizumab 200 mg will be administered every 3 weeks (Q3W) by IV infusion.&#xD;
PART 3 - Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) for 6 weeks followed by continuation of acalabrutinib monotherapy or combination therapy with acalabrutinib 100mg BID and pembrolizumab 200 mg Q3W as per Investigator discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-196</intervention_name>
    <description>oral</description>
    <arm_group_label>ACP-196 (Acalabrutinib) +PEM</arm_group_label>
    <other_name>Acalabrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenous</description>
    <arm_group_label>ACP-196 (Acalabrutinib) +PEM</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a hematologic malignancy as documented by medical records and with&#xD;
             histology based on criteria established by the World Health Organization (WHO).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.&#xD;
&#xD;
          -  Agreement to use contraception during the study and for 90 days after the last dose of&#xD;
             ACP-196 or 120 days after the last dose of pembrolizumab, if sexually active and able&#xD;
             to bear or beget children.&#xD;
&#xD;
          -  Completion of all therapy (including surgery, radiotherapy, chemotherapy,&#xD;
             immunotherapy, or investigational therapy) for the treatment of cancer ≥ 4 weeks&#xD;
             before the start of study therapy.&#xD;
&#xD;
          -  ANC ≥ 0.5 x 10^9/L or platelet count ≥ 50 x 10^9/L unless due to disease involvement&#xD;
             in the bone marrow.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  A life-threatening illness, medical condition or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of study drugs, or put the study outcomes at undue risk.&#xD;
&#xD;
          -  Central nervous system (CNS) involvement by lymphoma/leukemia&#xD;
&#xD;
          -  Any therapeutic antibody within 4 weeks of first dose of study drugs.&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN; and aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 3.0 x ULN.&#xD;
&#xD;
          -  Estimated creatinine clearance of &lt; 30 mL/min, calculated using the formula of&#xD;
             Cockcroft and Gault (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if&#xD;
             female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acerta Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Follicular</keyword>
  <keyword>Waldenstrom</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>marginal zone lymphomas</keyword>
  <keyword>hairy cell leukemia</keyword>
  <keyword>B cell acute lymphoid leukemia</keyword>
  <keyword>Acalabrutinib</keyword>
  <keyword>ACP-196</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Acalabrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>July 5, 2021</submitted>
    <returned>July 26, 2021</returned>
    <submitted>August 25, 2021</submitted>
    <returned>September 22, 2021</returned>
    <submitted>October 20, 2021</submitted>
    <returned>November 17, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

